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Abstract 
Taurine efflux occurs in association with cell swelling in both hyposmotic and isosmotic conditions 
and during cell shrinkage in apoptotic death. Release occurs through a leak pathway, is largely Ca2+-
independent and is sensitive to Cl– channel blockers. Taurine efflux elicited by hyposmolarity is re-
duced or suppressed by tyrosine kinase blockers and increased by tyrosine phosphatase inhibitors. 
The specific kinases involved are still unknown and may be different in the various cell types. Non-
receptor and scr-related protein kinases have been identified in some cells as elements that directly 
phosphorylate the taurine efflux pathway. Possible tyrosine kinase targets are the phosphinositide 
kinase (PI3K), which if inhibited, prevents the osmosensitive taurine efflux in brain cells, or the small 
GTP-binding proteins associated with remodeling of the cytoskeleton. The similar effects of tyrosine 
kinase modulators on volume-activated taurine fluxes and Cl– currents are suggestive of either a 
shared translocation pathway or a common step in the signaling network. The effects of tyrosine 
kinases on taurine efflux activated in isosmotic swelling and in the release associated with apoptosis 
are essentially unexplored. 
 




Taurine is released from diverse brain tissue preparations in response to a variety of stim-
uli, one of the most conspicuous being the reduction in external osmolarity.1 Taurine re-
lease is activated by cell membrane depolarization and in conditions of ischemia, hypoxia, 
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hyperammonemia and subsequent to generation of oxygen free radicals and membrane 
lipid peroxidation.2–5 Another stimulus consistently increasing taurine release from brain 
preparations is the activation of excitatory amino acid receptors by agonists such as gluta-
mate, kainate, NMDA, and quinolinic acid. Nitric oxide has been reported to increase tau-
rine efflux from cultured neurons and brain slices, an effect that could be either direct or 
through modulation of NMDA receptors.2 It is so far unclear whether the release of taurine 
in all these different conditions is triggered by a common factor, or whether in each case 
the release operates through different avenues. A possibility is that taurine release is pri-
marily a cell response to swelling. The bases to consider this possibility are, first, that all 
these conditions involve a certain degree of swelling and second, that swelling consistently 
evokes taurine efflux. Taurine is particularly suited for this osmolyte role, due to its meta-
bolic inactivity and its high concentration as a free solute in the cytosol.6 
 
Taurine efflux is evoked by hyposmotic and isosmotic cell swelling 
 
Swelling of brain cells may occur in hyposmotic or isosmotic conditions. The first condition 
is the consequence of hyponatremia of various origins.7 Isosmotic cell swelling, also re-
ferred as cytotoxic edema, occurs in association with ischemia, epilepsies, hepatic enceph-
alopathy, hyperammonemia, head trauma, and hypoglycemia.8–11 Swelling results from 
changes in ion distribution by dysfunction of ion transport mechanisms or by disruption 
of the membrane barrier subsequent to attack by free radical and lipoperoxidation, leading 
to ionic imbalance and overload, with the consequent water accumulation.8–11 In all cases, 
brain cell edema represents a situation of high risk, since the restriction to tissue expansion 
imposed by the rigid cranium, commonly leads to compression of small vessels generating 
episodes of ischemia, excitotoxicity, and neuronal death. 
Experimental paradigms in vitro and in vivo have been designed to simulate the condi-
tions leading to brain cell edema in vivo. The most commonly used model for hyponatremia 
is to expose cells or tissue to a hyposmotic medium made by decreasing the concentration 
of NaCl. Under these conditions, cells initially swell and then undergo an active process of 
volume recovery accomplished by the extrusion of intracellular osmolytes. Hyposmolarity 
elicits taurine efflux in essentially all cell types, including brain cells and also in brain tissue 
preparations.1,12,13 In vivo, taurine efflux from brain superfused with hyposmotic medium 
has been also consistently observed, and the increase of taurine in the extracellular space 
mirrors the decrease in intracellular levels.14,15,16 The magnitude of taurine efflux is propor-
tional to the reduction in osmolarity, its time course roughly parallels that of the volume 
recovery and blockade of taurine efflux or taurine deficiency impairs cell volume regula-
tion.1 In models of chronic hyponatremia in vivo, a continuous and progressive decrease in 
brain taurine levels is observed, to an extent that the intracellular pool is essentially de-
pleted.17 These results underlie the importance of taurine in the maintenance of normal 
brain water content, preventing the sequels of injury due to cell edema. 
There is general agreement that osmosensitive taurine efflux occurs through a leak path-
way, with no contribution of the Na+-dependent carriers.18 In most cell types taurine efflux 
is sensitive to Cl– channel blockers, such as 5-nitro-(3-phenyl-propylamino) benzoic acid 
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(NPPB), tamoxifen, and to the anion exchanger blockers niflumic acid, 4,41-diisothiocya-
natostil loene-2, 21-discultonic acid (DIDS) and pyridoxal phosphate.19–21 These features 
have raised the proposal of a common pathway (a Cl– channel-like molecule), for the os-
mosensitive transport of Cl–, taurine, and other organic osmolytes.19 This common path-
way hypothesis is not yet conclusive21 and awaits the molecular identity of the volume-
sensitive Cl– channel as well as more insight into the molecular nature of the taurine path-
way itself. 
While cell volume regulation after swelling evoked by hyposmolarity has been exten-
sively investigated, it is still unclear whether such regulation occurs in cytotoxic edema 
and to what extent organic osmolytes may participate in the volume correction, or at least 
contribute to reduce the magnitude of swelling. Taurine release occurs consistently under 
conditions of cytotoxic edema2 and its release is sensitive to Cl– channel blockers, suggest-
ing a similarity with the mechanism of release in hyposmotic conditions.22–24 However, it 
should be emphasized that even when cell swelling occurs by different mechanisms in 
each pathology, in most of them Cl– influx is a causal factor. Therefore, the inhibitory action 
of Cl– channel blockers may be exerted on the Cl– influx pathways, thus preventing swell-
ing and consequently, the primary cause of taurine release. 
 
Tyrosine kinases are involved in the hyposmolarity-evoked release of taurine 
 
Most studies aiming to understand the influence of tyrosine kinase-activated pathways 
during volume correction after hyposmotic swelling have been focused on the volume-
activated Cl– channel,25 while similar investigations for taurine efflux are still scarce. As 
mentioned before, the one pathway hypothesis for Cl– and taurine is not yet conclusive 
and therefore, results about signaling mechanisms modulating volume-activated Cl– chan-
nels should not be directly extrapolated to the osmosensitive taurine efflux. Similarly, 
transduction steps leading to activation of taurine efflux should not be naturally assumed 
to be the same for other organic osmolytes, nor even for other amino acids. This may be 
particularly true for tyrosine kinases as will be later discussed. 
Evidence in support of the involvement of tyrosine kinases in the osmosensitive taurine 
efflux relies on the effect of several tyrosine kinase blockers reducing the efflux of taurine, 
while correspondingly, agents which inhibit tyrosine kinase phosphatases and prolong ty-
rosine phosphorylation, potentiate taurine release. 
The general tyrosine kinase blockers tyrphostins, inhibit taurine release evoked by 
swelling in cultured cerebellar granule neurons and astrocytes,26,27 in the supraoptic nu-
cleus28 and in hippocampal slices29 (table 1). Ortho-vanadate potentiates taurine efflux in 
cerebellar granule neurons and astrocytes and in the supraoptic nucleus whereas it has no 
effect on taurine efflux in hippocampal slices. These differences, also found in other cells 
(see below) may be due either to the involvement of tyrosine phosphatases with different 
sensitivities to the blocker or to differences in the permeability of ortho-vanadate in the 
various preparations. 
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Table 1. Effect of tyrosine kinase blockers in hyposmotic-induced taurine efflux in brain 
preparations 
Cell type Agent [μM] Effect Reference 
Cerebellar granule neurons Tyrphostin AG18 50 Inhibition 90% (26) 
 Genistein 50 Inhibition 30%  
 PD98059 25 Unaffected  
Cerebellar astrocytes Tyrphostin A23 0.32–320 Inhibition 90% (27) 
 Tyrphostin A51 0.1–100 Inhibition 50–55%  
Supraoptic nucleus Tyrphostin B44 50 Inhibition 27–32% (28) 
 Genistein 50 Inhibition  
 PD98059 50 Unaffected  
Hippocampal slices Tyrphostin AG18 50 Inhibition 61% (29) 
 Tyrphostin AG112 100 Inhibition 29%  
 Tyrphostin AG879 25 Inhibition 78%  
 Genistein 100 Unaffected  
 Lavendustin A 1 Unaffected  
 Herbimycin A 10 Unaffected  
 PD98059 25 Unaffected  
 SB202190 25 Unaffected  
 
Tyrosine kinase blockers also reduce the hyposmolarity-elicited taurine efflux in non-
brain cells (table 2). In skate blood erythrocytes, tyrphostins reduce hyposmolarity-induced 
taurine release30 and in HeLa cells, genistein decreases and ortho-vanadate potentiates tau-
rine efflux. Also genistein reduces taurine efflux in trout erythrocytes, but in the latter cells, 
the release is either unaffected or reduced by ortho-vanadate.32 In a Langendorff heart 
preparation, taurine efflux is reduced by genistein and lavendustin A.33 Remarkably, this 
is the only study in vivo, addressing the influence of tyrosine kinases on the mechanism of 
taurine release in hyposmotic conditions. 
 
Table 2. Effect of tyrosine kinase blockers in hyposmotic-induced taurine efflux in nonbrain 
preparations 
Cell type Agent [μM] Effect Reference 
Skate red blood cells Tyrphostin 46 25–200 Inhibition (30) 
 Tyrphostin A23 25–200 Inhibition 50%  
 Genistein 25–200 Stimulation <20%  
 PD98059 25–200 Stimulation <20%  
Trout red blood cells Genistein 45–100 Inhibition (32) 
Jurkat T-cells Herbimycin A 10 Unaffected (53) 
HeLa cells Genistein 100 Inhibition 60%* (31) 
Langendorff preparation Genistein 1 Inhibition (33) 
 Lavendustin A 0.5 Inhibition  
* Recalculated from (31) 
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While taurine efflux stimulated by hyposmolarity is clearly affected by tyrosine kinase 
blockers, other amino acids (GABA and glutamate) which are also released from brain cells 
by the hyposmotic stimulus, are insensitive to tyrosine kinase blockers, suggesting a lack 
of influence of these kinases.29 A similar insensitivity to Cl– channel blockers, in contrast to 
taurine, suggests a different pathway for the osmosensitive release of these amino acids.29 
 
In most cell types, the specific kinases involved in the osmosensitive taurine efflux 
have not yet been identified 
 
The consistent effect of tyrosine kinase blockers reducing taurine efflux in hyposmotic con-
ditions, point to these enzymes as part of the osmotransduction signaling, connecting the 
change in cell volume and the activation of the taurine efflux pathway. So far, though, in 
most cells the specific kinases involved and the sites of their action remain to be identified. 
The most consistent work on the involvement of tyrosine kinases in hyposmolarity-activated 
taurine release has been carried out by Goldstein and coworkers, in a series of studies in 
the skate nucleated erythrocytes. The hyposmolarity-induced release of taurine in these 
cells appears to occur through the band 3 anion exchange protein.34 Taurine release is re-
duced by tyrphostin A23, although it is insensitive to other tyrphostins and to genistein.30 
Hyposmosis leads to band 3 phosphorylation by the tyrosine kinases p76syk and p56lyn30 
and p72syk directly phosphorylates the cytoplasmic domain of the band 3 protein with a 
time course parallel to that of the swelling-activated taurine efflux.30 Accordingly, the 
p72syk inhibitor piceatannol blocks, at about the same concentration, both taurine efflux 
and p72syk-dependent band 3 phosphorylation.30 Moreover, the phosphatase blocker per-
vanadate similarly potentiates taurine efflux and the activity of p72syk phosphorylation.30 
In this same preparation, various experimental paradigms were used to produce cell swell-
ing with differences in the intracellular ionic strength, as this parameter seems to regulate 
the set point for taurine efflux activation by cell swelling.35,36 The effect of intracellular 
strength reduction on the activity of the two tyrosine kinases involved in the band 3 phos-
phorylation and taurine efflux was examined, and results are suggestive of some sensitiv-
ity of p72syk and p56lyn to the change in intracellular ionic strength.37 In this respect, in 
the supraoptic nucleus, the magnitude of the effect of tyrosine kinase and phosphatase 
blockers is dependent on the external osmolarity, suggesting that tyrosine kinases modu-
late the sensitivity to hyposmolarity rather than the efflux pathway activation.28 
The src-related tyrosine kinase p56lck is found to be a key signaling element for os-
mosensitive Cl– currents in lymphocytes, as shown by its activation upon swelling, sup-
pression of osmosensitive currents in p56lck-deficient cells by genetic knockout and its 
restitution after retransfection of the kinase.38 The involvement of this kinase on taurine 
efflux has not yet been examined. 
Apart from these studies in blood cells, the tyrosine kinases involved in taurine efflux, 
and in that of other osmolytes as well, have not been identified. This is further complicated 
because tyrosine kinases are steps in the signaling cascades of numerous cell responses, 
many of which are activated by processes occurring in association with swelling and vol-
ume regulation, such as cell adhesion and retraction, reorganization of the cytoskeleton, 
and gating of stretch-activated channels. Besides, swelling is a stressful condition for the 
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cells, also activating signals associated with stress responses. Therefore, even the identifi-
cation of the kinases activated by hyposmolarity (fig. 1) may not be sufficient to ascribe 
them to the activation or operation of osmolyte extrusion pathways, including those for 
taurine. Examples of this situation are the phosphorylation by hyposmotic swelling of the 
mitogen-activated protein (MAP) kinases extracellular signal-related kinase-1/2 (ERK1/ 
ERK2) observed in various cell types.25,39 This reaction mediates the swelling-induced tran-
scription of early expression genes,40 the volume-sensitive channels in astrocytes41 and tau-
rocholate excretion in hepatocytes;39 but in most cell types and brain preparations such as 
cerebellar granule neurons, hippocampal slices, supraoptic nucleus, intestinal 407 cells and 
skate erythrocytes, even when MAP kinases are activated by hyposmolarity, preventing 




Figure 1. Interactions between some membrane associated receptors and signaling cas-
cades involving tyrosine kinases and tyrosine kinase-activated kinases. Enzymes in 
shaded circles are those activated by hyposmolarity. Receptors may be activated by ad-
hesion reactions or by clustering due to membrane cytoskeleton reorganization as a con-
sequence of swelling. TKR: tyrosine kinase receptors, GPCR: G protein coupled receptors, 
FAK: focal adhesion kinase, PI3K: phoshoinositide 3-kinase, SAPKS: stress-activated ki-
nases, ERK1/2: extracellular regulated kinases 1 and 2, MEK: MAPK/ERK-kinase, GEFs: 
guanine exchange factors, GAPs: GTPase-activating proteins, srck: src-related kinases, 
Rhok: Rho-kinase. 
 
An attractive hypothesis recently considered is that the integrin receptor could play a 
role in the sensing of cell volume changes by detecting membrane expansion or unfolding 
of membrane invaginations.43 Integrin activation, possibly by receptor clustering, could 
initiate a signaling cascade via focal adhesion kinase (FAK), which is known to be activated 
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by hyposmolarity. FAK, in turn, connects with a variety of signaling proteins such as src-
related protein kinases, PI3K and small GTP-binding proteins associated with remodeling 
of the cytoskeleton. All these proteins have been found to be activated by hyposmolarity 
in different cells and many of them are related to taurine (or Cl–) corrective fluxes. Besides 
the already discussed link of taurine release with src-related kinases and other nonreceptor 
kinases in blood cells, other elements of this signaling cascade involved in osmolyte fluxes 
include the small GTPase p21Rho,44,45 and particularly the phosphoinositide kinase PI3K. 
This enzyme, which is a key element in signaling networks connecting with integrins, FAK, 
src-related kinases and tyrosine kinase membrane receptors, appears to have a relevant 
role in the mechanisms of taurine release. In cerebellar granule neurons, astrocytes, and 
hippocampal slices, hyposmolarity activates PI3K, and this reaction is blocked by wort-
mannin (fig. 2A).26,29 This agent is also a potent blocker of hyposmotic taurine release in 
these preparations (fig. 2B), suggesting a direct link of PI3K and the activation or/and op-
eration of the taurine efflux pathway. Wortmannin also blocks anion fluxes activated by 
hyposmolarity in various cell types.44,47,48 The similar effect of tyrphostins and wortmannin 
on taurine efflux illustrated in figure 2 is suggestive of PI3K as a main target of tyrosine 




Figure 2. Effect of tyrosine kinases and PI3K inhibition on the osmosensitive taurine efflux 
hippocampal slices. (A) Hyposmotic (30%) medium activates PI3K, sensitive to wortman-
nin. I: isosmotic, H: 30%, hyposmotic, H1W: 30% hyposmotic + 100 nM wortmannin. Rep-
resentative results of three independent experiments are shown. PI3K was quantified by 
detection of the phosphorylated form of Akt phosphorylated at Ser-473. Lower panel 
shows the % of activity respectively to the isosmotic condition. (B) Inhibitory effect of 50 
μM tyrphostin AG18 (s) and 100 nM wortmannin (n) on taurine efflux elicited by 30% 
hyposmotic medium (l) (arrow) from hippocampal slices preloaded with 3H-taurine. 
Data represent the radioactivity released per min expressed as percentage of the total in-
corporated and are means ± SE (n = 6). Details of the experimental conditions as in Ref. 
29. 
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Tyrosine kinase receptors such as integrin, associated with many of those signaling ele-
ments may also have an influence on osmolyte release, as suggested by a study on my-
oblasts, in which taurine efflux is activated by thrombin and hyposmolarity, with similar 
characteristics.46 The idea of integrin or other membrane receptors acting as a very early 
and basic mechanism of the signaling osmotransduction cascade, might also explain the 
many common effects of tyrosine kinases on Cl– and taurine fluxes, and possibly on other 
organic osmolytes as well. 
 
Are tyrosine kinases involved in the mechanism of taurine release in isosmotic condi-
tions? 
 
As previously mentioned, taurine efflux is elicited in isosmotic conditions by a variety of 
stimuli, most of them having in common some extent of cell swelling due to intracellular 
ion redistribution. The mechanisms of taurine release in these conditions are still poorly 
defined and may or may not be similar to those activated by hyposmotic swelling. The 
influence of tyrosine kinases on taurine release is essentially unknown. Only two reports 
document the inhibitory effect of genistein and lavendustin on taurine release evoked by 
ischemia-reperfusion in brain and heart.49,50 It should be noticed that, similar to hyposmo-
larity, or even more, ischemia evokes a large number of reactions and cell responses, many 
of them involving tyrosine kinase phosphorylations, thus making it difficult to identify 
among those activated by the ischemic condition, which are directly related to the mecha-
nism of taurine release. 
 
Taurine release and apoptosis 
 
Cell shrinkage is one of the hallmarks of apoptosis, though the mechanisms leading to this 
remarkable reduction in cell volume are still poorly understood. Moderate increases in 
external osmolarity inhibit apoptosis, suggesting an active role of cell volume as part of 
the signals leading to cell death.51 Increasing external osmolarity may prevent the loss of 
osmotic solutes, and cell shrinkage, which may be a determinant in the initiation of the 
apoptotic events. Taurine appears to be one of those osmolytes. In Jurkat T lymphocytes, 
apoptosis induced by stimulation of the CD95 receptor, evokes a release of taurine.52 An 
apoptosis-associated taurine release has been also found in cerebellar granule neurons.53 
At variance with the osmosensitive release of taurine, the apoptosis-related taurine efflux 
is insensitive to Cl– channel blockers.52,53 The influence of tyrosine kinases is essentially 
unknown, with only one report in Jurkat cells showing that src-related kinases are not in-





The release of taurine associated with cell volume regulation is well established in condi-
tions of hyposmolarity and tyrosine kinases likely play a critical role in the mechanisms of 
this release. The present knowledge, however, is still fragmentary, with studies carried out 
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in different cell types or tissue preparations, different blockers and different experimental 
approaches, which makes it difficult to identify the specific tyrosine kinases involved in 
each cell type. As for the release of taurine in isosmotic conditions, the influence of tyrosine 
kinases is essentially unexplored, as is that of the apoptosis-associated taurine efflux. This 
is an interesting avenue for future research, which may give important clues about the 
similarities and dissimilarities of taurine release evoked by different stimuli. 
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